News - iladatuzumab vedotin (DCDS0780A)

almost3years

Anti-CD79B Antibody-Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study. (PubMed, Clin Cancer Res)

DCDS0780A as the TDC format for CD79B was tested at higher doses than its ADC counterpart investigated earlier, leading to deep responses. However, dose intensity was limited by ocular toxicities seen at the higher doses indicating that the TDC format was unable, in the current study, to expand the therapeutic index for the CD79B target. The encouraging anti-tumor activity advocates continuation of investigations into novel ADC technologies.

almost 3 years ago

Clinical • P1 data • Journal

CD79B (CD79b Molecule)

Rituxan (rituximab) • iladatuzumab vedotin (DCDS0780A)

5years

A Study of Escalating Doses of DCDS0780A in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov)

P1, N=66, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed

5 years ago

Clinical • Trial completion • Combination therapy

CD19 (CD19 Molecule)

Rituxan (rituximab) • Gazyva (obinutuzumab) • iladatuzumab vedotin (DCDS0780A)